术前RAS突变检测或可指导甲状腺切除范围
研究对细针穿刺样本按3类不确定细胞学分类行NGS检测RAS突变。93例患者94个结节检出RAS,86例手术,76%结节为恶性,滤泡型乳头状癌占83%。HRAS突变癌症风险最高,或可指导甲状腺切除范围。
要点
- 术前RAS突变阳性结节恶性风险高,滤泡型乳头状癌最常见。
- HRAS突变癌症风险最高,其次NRAS,KRAS最低。
- RAS突变检测结果或可辅助决定甲状腺切除范围。
核心结论
- 术前甲状腺结节RAS突变检测提示较高癌症风险,HRAS和NRAS风险更高。
- RAS相关恶性肿瘤多为滤泡型乳头状癌,可能指导手术范围。
研究设计与样本
- 前瞻性研究,对3类不确定细胞学分类的细针穿刺样本行NGS检测N-、H-、K-RAS突变。
- 93例患者94个结节术前检出RAS,其中86例接受手术(69%全甲状腺切除,29%腺叶切除)。
主要发现
- RAS阳性结节中76%为恶性,滤泡型乳头状癌占83%。
- HRAS突变癌症风险92%,NRAS 74%,KRAS 64%(P = .05)。
- 年龄、性别、RAS亚型、突变等位基因频率、结节大小、细胞学类别及超声特征均与恶性无显著关联。
- 超声单发结节患者中仅60%为单灶低危包裹性滤泡型乳头状癌或良性疾病。
关键数值与推荐
- RAS阳性结节恶性率76%。
- HRAS突变癌症风险92%,NRAS 74%,KRAS 64%(P = .05)。
- 滤泡型乳头状癌占RAS相关恶性肿瘤的83%。
- 超声单发结节中单灶低危包裹性滤泡型乳头状癌或良性病变仅占60%。
临床怎么用
- 对不确定细胞学结节行术前RAS突变检测,辅助癌症风险评估。
- RAS突变阳性尤其HRAS/NRAS时,考虑更积极的手术范围如全甲状腺切除。
- 结合超声单发结节特征,权衡腺叶切除与全切的利弊。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Preoperative detection of RAS mutations can contribute to cancer risk assessment in indeterminate thyroid nodules, although RAS is not always associated with malignancy. METHODS: Fine-needle aspiration samples classified in 1 of 3 indeterminate cytology categories were prospectively tested for N-, H-, and K-RAS mutations using next-generation sequencing assay. RESULTS: In the study, 93 patients with 94 nodules had preoperative RAS detected, of whom 86 patients had an operation (69% total thyroidectomy, 29% lobectomy). In total, 76% of RAS-positive nodules were malignant and follicular variant papillary thyroid cancer was the most common cancer type (83%). HRAS mutations had the greatest risk of cancer (92%) followed by NRAS (74%) and KRAS (64%; P = .05). No preoperative variables were associated with malignancy including age (P = .07), sex (P = .49), RAS isoform (P = .05), mutational allelic frequency (P = .49), nodule size (P = .14), cytology category (P = .63), or ultrasound bilaterality (P = .24), multifocality (P = .23), or presence of ≥1 suspicious feature (P = .86). Only 60% of patients with a unifocal nodule on ultrasound had single focus low-risk encapsulated follicular variant papillary thyroid cancer or benign disease. CONCLUSION: Preoperative RAS mutation detection in thyroid nodules carries a substantial risk of cancer with a greater risk associated with HRAS and NRAS. Most RAS malignancies are follicular variant papillary thyroid cancer, which may inform the extent of operation.
引用
- Patel SG, Carty SE, McCoy KL, et al. Preoperative detection of RAS mutation may guide extent of thyroidectomy. Surgery. 2016. PMID: 27863786. doi:10.1016/j.surg.2016.04.054
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。